# Study Evaluating ReFacto in Hemophilia A

> **NCT00038909** · NA · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 103 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** BDDrFVII

## Key facts

- **NCT ID:** NCT00038909
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-09
- **Primary completion:** 2001-05
- **Final completion:** 2001-05
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2013-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038909, "Study Evaluating ReFacto in Hemophilia A". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00038909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*